The Library
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes : three randomized trials
Tools
Tools
Tools
DIRECT (Diabetic Retinopathy Candesartan Trials) Program Study Group (Including: Bilous, Rudy, Chaturvedi, Nish, Sjølie, Anne Katrin, Fuller, John, Klein, Ronald, Orchard, Trevor, Porta, Massimo and Parving, Hans-Henrik). (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes : three randomized trials. Annals of Internal Medicine, Vol.151 (No.1). pp. 11-20.
Research output not available from this repository, contact author.Abstract
Background: Microalbuminuria in diabetes is strongly predictive of nephropathy, end-stage renal disease, and premature cardiovascular morbidity and mortality. Effective preventive therapies are therefore a clinical priority.
Objective: To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes.
Design: 3 randomized trials of the DIRECT (Diabetic Retinopathy Candesartan Trials) Program.
Setting: 309 secondary care centers.
Patients: 3326 and 1905 patients with type 1 and type 2 diabetes, respectively. Most were normotensive, and all had normoalbuminuria (median urinary albumin excretion rate, 5.0 µg/min).
Intervention: Candesartan, 16 mg/d increasing to 32 mg/d, versus placebo. Assignment was done centrally using an interactive voice-response system. Patients, caregivers, and researchers were blinded to treatment assignment. During a median follow-up of 4.7 years, 793 patients discontinued therapy and 63 were lost to follow-up.
Measurements: Urinary albumin excretion rate, assessed annually by 2 overnight collections; if it was 20 µg/min or greater, then 2 further collections were done. The primary end point was new microalbuminuria (3 or 4 collections of urinary albumin excretion rate ≥20 µg/min). The secondary end point was rate of change in albuminuria.
Results: Individual and pooled results of the 3 trials showed that candesartan had little effect on risk for microalbuminuria (pooled hazard ratio, 0.95 [95% CI, 0.78 to 1.16]; P = 0.60). Pooled results showed that the annual rate of change in albuminuria was 5.53% lower (CI, 0.73% to 10.14%; P = 0.024) with candesartan than with placebo.
Limitations: Investigators recruited mainly normotensive patients or patients with well-controlled hypertension who were at low overall vascular risk, which resulted in a low rate of microalbuminuria. Studies were powered for retinal and not renal end points.
Conclusion: Candesartan, 32 mg/d, for 4.7 years did not prevent microalbuminuria in mainly normotensive patients with type 1 or type 2 diabetes.
Primary Funding Source: AstraZeneca and Takeda.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) | ||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | Annals of Internal Medicine | ||||
| Publisher: | American College of Physicians | ||||
| ISSN: | 0003-4819 | ||||
| Official Date: | 7 July 2009 | ||||
| Dates: |
|
||||
| Volume: | Vol.151 | ||||
| Number: | No.1 | ||||
| Page Range: | pp. 11-20 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
